Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Over the last 12 months, insiders at Anebulo Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Anebulo Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Anebulo Pharmaceuticals, Inc. have bought $105,079 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 400 shares for transaction amount of $2,634 was made by English Aron R. () on 2021‑12‑17.
2021-12-17 | 400 0.0016% | $6.59 | $2,634 | -43.79% | ||||
2021-12-14 | 412 0.0015% | $5.89 | $2,429 | -40.48% | ||||
2021-12-03 | 4,500 0.0153% | $5.93 | $26,685 | -42.67% | ||||
2021-12-02 | 13,836 0.0441% | $5.30 | $73,331 | -39.35% |
English Aron R. | 3362713 12.9668% | $1.59 | 4 | 0 | <0.0001% |